<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678871</url>
  </required_header>
  <id_info>
    <org_study_id>2016-01-18</org_study_id>
    <nct_id>NCT02678871</nct_id>
  </id_info>
  <brief_title>Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage</brief_title>
  <acronym>TAVI-LAAC</acronym>
  <official_title>Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is a common comorbidity of patients candidates to transcatheter&#xD;
      aortic valve implantation (TAVI). The management of chronic oral anticoagulation (OAC) for&#xD;
      the prevention of ischemic stroke is very challenging in this population of complex and frail&#xD;
      subjects. Since the percutaneous left atrial appendage (LAA) closure with the WATCHAMN device&#xD;
      proved promising safety and efficacy results in randomized comparisons with OAC (current&#xD;
      standard of care), the aim of the current study is to assess the feasibility and the early&#xD;
      safety of performing TAVI with the Lotus System and percutaneous LAA closure with the&#xD;
      WATCHMAN device at the same session.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early safety (composite endpoint of TAVI-related (according to VARC 2 criteria) and percutaneous LAA closure-related events at 30 days)</measure>
    <time_frame>30 Days</time_frame>
    <description>Early safety - composite endpoint of TAVI-related (according to VARC 2 criteria) and percutaneous LAA closure-related events at 30 days. Composite defined as all cause-mortality, all stroke (disabling and non-disabling), life threatening bleeding, acute kidney injury (stage 2 or 3, including renal replacement therapy), coronary artery obstruction requiring intervention, major vascular complications, valve-related dysfunction requiring repeat procedure, pericardial effusion requiring pericardial drainage, and LAA device embolization requiring surgical intervention</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Aortic Valve Disorder</condition>
  <arm_group>
    <arm_group_label>All study participants</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the LOTUS or Acurate Neo heart valve system (or subsequent CE marked iterations) and LAA closure with the WATCHMAN device in the same setting. Dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) will be prescribed for 6 months followed acetylsalicylic acid indefinitely. Follow-up will be performed after 1 month, 6 months and 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)</intervention_name>
    <description>Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the Lotus or ACURATE neo Heart valve system (or subsequent CE marked iterations)</description>
    <arm_group_label>All study participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WATCHMAN</intervention_name>
    <description>LAA closure with the WATCHMAN device</description>
    <arm_group_label>All study participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  TAVI candidates&#xD;
&#xD;
          -  Elderly patients with symptomatic, severe, calcific, native aortic valve stenosis,&#xD;
             assessed by echocardiography AVA up to 1.0 cm2 or AVAi up to 0.6 cm2m2 and mean&#xD;
             pressure gradient 40 mmHg or jet velocity 4 ms&#xD;
&#xD;
          -  Inoperable or at increased surgical risk (according to multidisciplinary heart team&#xD;
             decision)&#xD;
&#xD;
          -  Non-valvular AF (paroxysmal, persistent or permanent)&#xD;
&#xD;
          -  CHA2DS2-VASc ≥ score&#xD;
&#xD;
          -  HAS-BLED score ≥ 2&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Aortic annulus size ≥ 20 mm and ≤ 27 mm&#xD;
&#xD;
          -  Adequate LAA ostium diameter (17 31mm)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous TAVI&#xD;
&#xD;
          -  Previous LAA closure (surgical or percutaneous)&#xD;
&#xD;
          -  Previous RF ablation of AF&#xD;
&#xD;
          -  Need for long-term OAC (history of pulmonary embolism, mechanical heart valve)&#xD;
&#xD;
          -  Contraindication to aspirin&#xD;
&#xD;
          -  Relevant CAD requiring revascularization&#xD;
&#xD;
          -  Infective endocarditis&#xD;
&#xD;
          -  LV ejection fraction &lt; 20 percent&#xD;
&#xD;
          -  Cardiogenic shock or hemodynamic instability&#xD;
&#xD;
          -  Symptomatic carotid disease&#xD;
&#xD;
          -  Life expectancy &lt; 1 year&#xD;
&#xD;
          -  Severe renal failure (dialysis or serum creatinine level &gt; 3.0 mg/dl or 265 μmol/L)&#xD;
&#xD;
          -  CVE within the past 3 months&#xD;
&#xD;
          -  Acute complications occurring during TAVI procedure&#xD;
&#xD;
          -  Congenital unicuspid aortic valve&#xD;
&#xD;
          -  Femoral artery lumen diameter &lt;6.0 mm or &lt;6.5 mm (for the 23-mm valve or the 25-mm and&#xD;
             27-mm valves, respectively)&#xD;
&#xD;
          -  Documented LAA and/or LV thrombi&#xD;
&#xD;
          -  Severe MR&#xD;
&#xD;
          -  Atrial septal defect&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lorenz Räber, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital Bern, Universitätsklinik für Kardiolgie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lorenz Räber, Prof. Dr.</last_name>
    <phone>+41 31 632 21 11</phone>
    <email>lorenz.raeber@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock Zentrum für Innere Medizin Abteilung für Kardiologie</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hüesyin Ince, Prof.</last_name>
      <email>hueseyin.ince@vivantes.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Structural Heart Disease Interventions Unit - IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Milano</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federico De Marco, Dr. med</last_name>
      <email>federico.demarco@grupposandonato.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico &quot;G.Rodolico &quot;</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corrado Tamburino, Prof.</last_name>
      <email>tambucor@unict.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Angelillis, Dr. med</last_name>
      <email>angelillismarco@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Maria University Hospital,</name>
      <address>
        <city>Lisbon</city>
        <zip>1649-028</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fausto J. Pinto, Prof.</last_name>
    </contact>
    <contact_backup>
      <email>faustopinto@medicina.ulisboa.pt</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenz Räber, Prof. Dr.</last_name>
      <phone>+4131 632 21 11</phone>
      <email>lorenz.raeber@insel.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Valve Stenosis</keyword>
  <keyword>Left atrial appendage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

